Stock Options – Ipass http://www.ipass.net/ Wed, 21 Jul 2021 11:22:06 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 Passage Bio announces an incentive award for new nominees https://www.ipass.net/passage-bio-announces-an-incentive-award-for-new-nominees/ Wed, 21 Jul 2021 11:00:00 +0000 https://www.ipass.net/passage-bio-announces-an-incentive-award-for-new-nominees/

PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) – Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic drug company focused on developing transformative therapies for rare and monogenic central nervous system (CNS) disorders , announced today that it has granted an incentive to the company’s new commercial director, Mr Maria Törnsén, as part of an incentive plan adopted by its board of directors.

Passage Bio granted an option to purchase 200,000 common shares and 20,000 restricted stock units (RSU) to Ms. Törnsén as a significant incentive to her employment in accordance with the Nasdaq listing rule 5635 (c) (4). The stock options have an exercise price of $ 13.04 per share, which corresponds to the closing price of the common shares of Passage Bio on the grant date. The shares subject to stock options will vest over four years, with 25% of the shares vesting on the one year anniversary of the grant date, and the remainder vesting in 36 equal monthly installments by the continuation, subject to continued employment. Stock options have a term of 10 years and are subject to the terms and conditions of the stock option agreement. The RSUs will vest over four years, 25% of the RSUs being acquired on each of the first, second, third and fourth annual anniversaries of the first of the quarterly vesting dates of Passage Bio following the grant date, subject to the maintenance of the ’employment.

About Passage Bio

At Passage Bio (Nasdaq: PASG), our mission is to provide life-transforming gene therapies that transform the lives of patients with rare and monogenic CNS diseases that replace their suffering with limitless possibilities, while building lasting relationships with communities. that we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned Gene Therapy Program at the University of Pennsylvania to conduct our preclinical discovery and IND work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations which we then combine with our in-depth clinical, regulatory, manufacturing and commercial expertise to rapidly advance our strong pipeline of gene therapies optimized for clinical trials. As we work with speed and tenacity, we are always attentive to the patients who can benefit from our therapies. More information is available at www.passagebio.com.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of, and made in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: our expectations regarding the timing and the execution of planned milestones, including the initiation of clinical trials and the availability of clinical data resulting from these trials; our expectations regarding the ability of our employees and partners to execute key initiatives; our expectations regarding manufacturing plans and strategies; and the ability of our lead product candidates to treat their respective CNS monogenic target disorders. These forward-looking statements may be accompanied by words such as “aim”, “anticipate”, “believe”, “could”, “estimate”, “expect”, “foresee”, “objective”, “intend” , “May”, “could”, “plan”, “possible”, “possible”, “will fly”, “” and other words and terms with similar meanings. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop and obtain regulatory approval for our product candidates; the timing and results of preclinical studies and clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or studies additional, or may not approve or delay the approval of our drug candidates; the occurrence of adverse safety events; the risk that positive results from a preclinical study or clinical trial will not be replicated in subsequent trials, or that the success of early-stage clinical trials may not be predictive of clinical trial results at a later stage later stage; failure to protect and enforce our intellectual property and other proprietary rights; our reliance on collaborators and other third parties for the development and manufacture of product candidates and other aspects of our business, which are beyond our total control; risks associated with current and potential delays, work stoppages or supply chain disruptions caused by the coronavirus pandemic; and other risks and uncertainties described in the Risk Factors section in documents the Company files from time to time with the Securities and Exchange Commission (SEC) and other reports filed with the SEC. Passage Bio assumes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

For more information, please contact:

Bio Investors Passage:

Stuart henderson
Bio Passage
267-866-0114
shenderson@passagebio.com

Bio Media Passage:

Gwen Fisher
Bio Passage
215-407-1548
gfisher@passagebio.com

Source link

]]>
Bioasis Technologies Inc.Announces Stock Option Grants, Jeffrey Sprouse Appointed Preclinical Program Director https://www.ipass.net/bioasis-technologies-inc-announces-stock-option-grants-jeffrey-sprouse-appointed-preclinical-program-director/ Tue, 20 Jul 2021 20:10:46 +0000 https://www.ipass.net/bioasis-technologies-inc-announces-stock-option-grants-jeffrey-sprouse-appointed-preclinical-program-director/

NEW HAVEN, Connecticut, July 20, 2021 (GLOBE NEWSWIRE) – BIOASIS TECHNOLOGIES INC. (TSXV: BTI; OTCQB: BIOAF), (the “Company” or “Bioasis”), a research-stage preclinical biopharmaceutical company developing its proprietary xB3™ technology platform for delivering therapy across the blood-brain barrier (“BBB”) and treating central nervous system (“CNS”) disorders in areas of high unmet medical needs, including brain cancers and neurodegenerative diseases it granted stock options to acquire a total of 1,367,606 common shares effective June 30, 2020 at a price of $ 0.38 per share to the directors and officers of the Company and an investor relations consultant. All options expire five years after the grant date and are governed by the terms of the Company’s stock option plan. Options are issued as annual compensation instead of cash compensation, as the company prioritizes investment in R&D enhancing partnerships.

The company also announced the appointment of Dr. Jeffrey Sprouse PhD as Director of the Preclinical Program. Dr. Sprouse brings over 20 years of drug discovery experience to his role at Bioasis. Trained as a neuropharmacologist, he has held leadership positions in leading pharmaceutical organizations, having served as a project leader for a variety of multidisciplinary drug discovery programs at Pfizer and chair of the Committee for Early Project Development at Lundbeck . Since 2010, Dr. Sprouse has been an industry consultant, managing all aspects of preclinical programs. Dr Sprouse received his doctorate from Cornell University Medical College and postgraduate training from the Department of Psychiatry at Yale University. He is author / co-inventor of over 60 scientific papers, book chapters and patents.

Dr. Deborah Rathjen, Executive President of Bioasis, welcomed Dr. Sprouse to the Bioasis team: number of clinical applicants.

Dr. Sprouse commented, “Bioasis has exciting technology for the delivery of BBB drugs, one of the main challenges in unlocking the potential of biologic therapies for the treatment of CNS disorders. This technology is coupled with an exciting pipeline addressing areas of unmet medical need. I am happy to join Bioasis and look forward to working with the team to achieve key milestones.

On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen, Ph.D., Executive Chairman of the Board

Follow on:
Facebook
Instagram
LinkedIn
Twitter

RTC-CRP

About bioase
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3™, a proprietary technology for delivering therapy across the blood brain barrier and treating CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutic products across the blood-brain barrier represents the final frontier in the treatment of neurological disorders. Bioasis internal development programs are designed to develop symptomatic and disease-modifying treatments for diseases and disorders related to the brain. For more information about the Company, please visit www.bioasis.us.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts:

Deborah Rathjen, Ph.D., Executive Chairman of the Board and Chief Executive Officer
deborah@bioasis.us
203-533-7082

Investor contact:
Graeme dick
Colwell Capital Corp.
graeme@colwellcapital.com
403-561-8989

Main logo

Source link

]]>
Robinhood Warns Retail Slows Down, Particularly In Cryptocurrencies https://www.ipass.net/robinhood-warns-retail-slows-down-particularly-in-cryptocurrencies/ Mon, 19 Jul 2021 15:00:14 +0000 https://www.ipass.net/robinhood-warns-retail-slows-down-particularly-in-cryptocurrencies/

In this photo illustration, the Robinhood Markets logo is seen on a smartphone and PC screen. (Photo illustration by Rafael Henrique / SOPA Images / LightRocket via Getty Images)

SOPA Pictures | LightRocket | Getty Images

The Robinhood stock trading app – which is expected to go public as early as next week – has warned of a potential slowdown in trading income and new clients as the retail investment boom begins to slow.

“We expect our revenues for the quarter ended September 30, 2021 to be lower than the quarter ended June 30, 2021, due to lower levels of trading activity from record levels of trading activity, in particularly in cryptocurrencies, during the three months ended June 30, 2021, and the expected seasonality, ”Robinhood said in a prospectus published Monday.

The slowdown comes from booming levels. The Menlo Park, Calif., Free trade pioneer estimates second-quarter 2021 revenue to be between $ 546 million and $ 574 million. This would be an increase of 129% from the $ 244 million in the second quarter of 2020. The second quarter results are expected to be lower than the $ 522 million in revenue generated in the first quarter of this year.

However, the company estimates a net income loss of between $ 537 million and $ 487 million in the second quarter of 2021, compared to a loss of $ 1.4 billion in the first quarter.

Robinhood – which offers trading in stocks, cryptocurrencies and options, as well as cash management accounts – benefits from more speculative business practices on the part of its clients. Options trading accounts for around 38% of income while crypto accounts for 17% of income. Additionally, levels of margin trading and stock lending were high in 2021.

A stagnation in options, margin trading and crypto – with bitcoin priced below $ 30,000 – could hurt Robinhood’s growth as it heads into one of the biggest public debuts in the world. year.

Robinhood also said that he expected the growth rate of new clients to be lower in the third quarter of 2021, compared to the second quarter, “due to the unusually strong interest in trading, particularly in cryptocurrencies. , which we have experienced in the three months ended June 30, 2021 and the seasonality of overall business operations, ”said S1.

Robinhood expects its app to have 22.5 million funded accounts – those linked to a bank account – in the second quarter, up from a total of 18 million in the first quarter of 2021.

Robinhood – whose long-standing mission is to ‘democratize’ investing – has seen record levels of new, younger traders entering the stock market during the pandemic. This surge continued in 2021, marked by frantic exchanges around so-called memes actions.

The company hinted at clients who created accounts around GameStop’s short squeeze in January, but may have stopped trading as the frenzy died down.

“We have experienced strong growth in the number of new customers in the first six months of 2021,” the file said. “We do not know if, in the long run, the cohorts made up of these new clients will have the same characteristics as our previous cohorts. As long as these new clients do not increase their cumulative net deposits or their frequency of trading on our platform. As new clients have joined in previous periods, our ability to expand and develop our relationship with these clients will be affected. ”

Robinhood is looking for a market valuation of up to $ 35 billion on its next IPO. The stock trading app will attempt to sell its share in a range of $ 38 to $ 42 per share.

– with reporting from CNBC’s Kate Rooney.

Robinhood is a quintuple CNBC 50 disruptor company that topped this year’s list.

Sign up for our original weekly newsletter that goes beyond the list, providing a deeper insight into the CNBC Disruptor 50 companies and founders who continue to innovate across all sectors of the economy.


Source link

]]>
Rising support level https://www.ipass.net/rising-support-level/ Sun, 18 Jul 2021 19:23:34 +0000 https://www.ipass.net/rising-support-level/

The resistance level, after remaining at 15,800 strikes for two consecutive weeks, for Nifty rose 200 points to 16,000 strikes, while the support level jumped to 15,900 strikes from 15,000 strikes, where it stood. for four consecutive weeks.

Tech stocks were the main influence on the market movement last week. Tech stocks Wipro, L&T, Tech Mahindra, HCL Tech pushed the NSE Nifty above 15,900 points after six weeks of consolidation. However, going forward, analysts expect bank stocks to remain the center of attention as bank results will.

However, the top 10 Nifty stocks remained limited in their range and were trading below resistance levels due to higher call bases.

Dhirender Singh Bisht, Senior Research Analyst (Derivatives) at SMC Global Securities Ltd, said: “The Nifty Indices hit their all-time highs over the past week, but still have failed to surpass the key psychological bar. of 16,000 points as bank securities. remain behind. However, computer metal and pharmaceuticals stocks shone to support the markets. ”

On the options front, derivative activity is relatively weak compared to the past two weeks. Given the recent Put writing and Nifty’s move above 15,900 strikes, derivative analysts expect Nifty to bias positively towards the 16,200 level. Therefore, long positions are recommended up to what the Nifty is holding above the 15,800 level, which is the main selling base. A move below 15,800 may keep the current range limit move intact.

The highest Call OI is 16,000 strikes followed by 16,200 / 16,500 / 16,100 / 15,900 strikes. Additionally, 16,000 / 16,500 / 16,300 / 15,950 strikes witnessed a reasonable addition to the OI appeal.

On the Put side, 15,900 strikes recorded the maximum Put OI followed by 15,900 / 15,880 15,700 / 15,300 strikes. Moderate Put OI buildup is seen at 15,900 / 15,700 / 15,650 / 15,300 strokes.

“On the derivatives front, the fight between the bulls and the bears has been observed in a range of 15,900 points and 16,000 points, as all the perpetrators hold maximum open interest at 16,000 strikes, while the authors of put saw open interest added in 15,900 puts, ”Bisht said.

BSE Sensex closed the week ended July 16, 2021 at 53,140.06 points, a net recovery of 753.87 points or 1.43%, from the previous week’s close of 52,386.19 points.

Posting a rebound of 233.60 points or 1.48%, NSE Nifty finished the week at 15,923.40 points from 15,689.80 points a week ago.

Bisht forecast:

“The technical setup suggests that the 36,000 mark will act as crucial resistance for the banking index above which we may see another breakout on the charts that could take Nifty to all-time highs and above the 16,000 level this time around while Bank Nifty could hit the 36,800 level in upcoming sessions. ”

India VIX was down 4.60% to 11.70. The derivatives segment saw a slight increase in the volatility index during the penultimate week. A surge in volatility is expected given the results of nearly 12 index companies next week.

Implied volatility (IV) of calls closed at 11.62 percent, while that of puts closed at 12.07 percent. The week’s Nifty VIX closed at 12.27%. OI’s PCR for the week closed at 1.42, “Bisht noted.

In the M&O space, FII activity has remained sluggish since the start of the M&O series in July. The FII bought index futures worth Rs 3,825 crore, equity futures contracts worth Rs 1,037 and Rs 793 during the week.

Smart bank

The NSE banking index closed the week at 35,751.80 points, a net gain of 679.85 points or 1.93%, from the previous week’s close of 35,071.95 points.

Since most banking heavyweights hover near their highest calling bases, moving above their calling bases will therefore be crucial for banking performance. According to ICICI Direct.com, the strike of 36,000 people is expected to be a critical level and sustainability above this level could open the door to further benefits.

The market saw the addition of new long positions as the index moved towards its call base of 36,000 raises as well as a rise in the OI. Analysts believe that the current momentum should continue in the coming days.

F&O turnover

Products Contracts Revenue (Rs / cr) Premium (Rs / cr)

Futures contracts on indices 1,85,618 15,768.05 –

Futures contracts on shares 6 94 140 55 707.29 –

Options on indices 257,50,180 25,37,319.68 10,945.59

Stock options 26 46,642 2 17,627.38 3,315.00

F&O Total 2 92 76 580 28 26 422.40 14 260.59


Source link

]]>
What the “designer economy” promises and what it actually does https://www.ipass.net/what-the-designer-economy-promises-and-what-it-actually-does/ Sat, 17 Jul 2021 10:00:00 +0000 https://www.ipass.net/what-the-designer-economy-promises-and-what-it-actually-does/

The influencer is a common character in commedia dell’arte on the Internet. Often a conventionally attractive white woman, she shows off her ambitious lifestyle through social media channels. She accumulates many followers, then makes a living having companies sponsor the content of her glamorous life. The influencer snapshot emerged over the nineties from multimedia-rich platforms like Instagram and Snapchat, where the goal was to forge an image as polished and polished as possible. The influencers were social media users as celebrities, with much of the vanity and pointlessness that the comparison implies. Right now, the connotations of being an influencer are mostly negative: edited selfies, tasteless captions, false relativity, staged private jet photos, and unmarked sponsorships. As a result, social media platforms are adopting a new buzzword as their successor: “designer”.

“Creator” is a term with a healthier air, evoking an Internet in which we are all artisan blacksmiths plying our digital profession. But what exactly the word implies beyond that is subject to debate. Taylor Lorenz report for Atlantic, the term was initially marketed by YouTube, as early as 2011, as an alternative to a vocabulary like “YouTube star”, which seemed to imply that only a few famous personalities could be successful on the platform. But it’s now used to describe virtually anyone who produces any form of content online. TikTok users are “TikTok makers”. Members of the Clubhouse invite-only real-time voice chat application are “Audio Creators”. OnlyFans, a market primarily used for pornography, is home to “adult content creators”.

Even proponents of the so-called “designer economy,” the network of new platforms and tools meant to serve creators, cannot quite agree on what the term means or who it includes. His ascent triggered a semantic debate which tends towards the solipsist. “I think all influencers are designers; maybe not all creators are influencers, ”Nicole Quinn, partner at venture capital firm Lightspeed Venture Partners, told me. Lightspeed’s investments in the creator economy include Cameo, a platform best known for personalized video messages that celebrities sell to fans, and Outschool, a marketplace for online courses. For Quinn, the difference in terminology comes down to success: influencers are already famous; creators strive to be. Li Jin, the founder of creator-economy investment firm Atelier Ventures, instead defined creators in terms of income. “Anyone whose fame comes from online channels, if they are able to earn an income from that influence, I consider it to be the economy of the creators. “

Despite its vagueness, the term “creator” is being adopted as synonymous with a new generation of social media spaces believed to be designed to support content producers in new ways. Where Facebook and Twitter ad platforms take advantage of our data and attention without giving much in return, Clubhouse and OnlyFans promise to deliver more value to users by enabling what Quinn of Lightspeed calls “monetization.” direct ”. “Instead of selling company ads on the basis of overall engagement, creators can be paid by their individual viewers, who can purchase subscriptions, send tips, or fund new projects. The word ‘influencer’ emphasized the magnetic effect of a person on his followers, a nebulous charisma easily turned to marketing. “Creator”, on the other hand, emphasizes that everyone who posts on social networks produces something, being involved in the effort collective aiming to make user-generated platforms compelling and therefore profitable. This idea has proven to be highly marketable: the economy of creators has would have $ 1.3 billion in investment funding in 2021 so far, almost three times the funding it received in 2020.

Companies in the creative economy have devised various revenue models as alternatives to advertising. Subscription platforms like Patreon, Substack, and Buy Me a Coffee charge a percentage of users’ income in exchange for posting and paywalling their content. Apps like Linktree, Beacons, and Feedlink offer a service that, for a monthly subscription, expands website links that are found in the bio of social media accounts, directing fans to a creator’s various content channels. . Non-fungible token (NFT) marketplaces like Foundation, Rarible, and SuperRare allow creators to sell expensive digital art in exchange for commissions. On Twitch, a site where users can stream live content like video games, and Heygo, a streaming site that provides a virtual proxy for travel, viewers can access video streams for free, with the ability to send advice to hosts. According to Quinn, March 2020 was the “key inflection point” for this booming economy, as increased appetite for digital content and the loss of jobs in other industries during the pandemic prompted more people to try their luck as creators.

In some ways, the creator economy seems to empower the user. Rather than trying to play on social media algorithms, creators can theoretically count on more reliable income from supporters. They can choose the types of work they undertake, whether it’s newsletters, live broadcasts, or audio chats. “They don’t have to worry about beating the mainstream of the platform,” said Sam Yam, co-founder of Patreon, a pioneer of the creative economy. In Yam’s mind, making a living as a creator is an evolution of the so-called gig economy facilitated by companies like Uber and TaskRabbit. Subscribers pay to access someone’s unique talent or voice. “You care about the individual more than the task at hand,” Yam said. “It’s value exchanged for creativity. The model promises a more human and less automated interaction. What used to be called subscribers – the anonymous numbers that pile up on a profile page like fungible eyeballs – are now customers, supporters and customers.

But this emerging field, in many ways, looks like a gig economy for digital content. Participants are still precarious workers, who depend on the whims of business for their livelihood. Much like an Uber driver or twenty-dozen Instagram influencer, the designer is responsible for her own contributions to marketing, healthcare, and taxes. It earns money for the platform that hosts it without benefiting from the legal and financial protections of employee status, nor from the stock options generally granted to engineers, designers and managers of the platform. Meanwhile, social media giants are developing their own version of the creator economy in an effort to prevent users from fleeing to newer and smaller platforms. Last year, TikTok launched a Creator Fund to pay its users directly for popular content. Snapchat launched a similar program called Spotlight, which offers creators millions of dollars in compensation per month. Last week, Instagram owner Facebook announced that it would pay more than $ 1 billion to users of its platforms by 2022.

Anshuman Iddamsetty, a former podcast producer who now runs an erotic self-portrait-focused Patreon, which uses the pronouns “they” and “them”, told me that they are making enough of a living from this account and an OnlyFans page. But they said there is a gap between the platforms’ message that anyone can “build a freelance creative career,” as Patreon’s website claims, and the reality of being a solo entrepreneur. “Patreon doesn’t suddenly and magically make it easy to create your deliverables,” they said. Ambiguous guidelines can give platforms the power to block users or types of content at will; Patreon allows some forms of adult content, but Iddamsetty, who describes himself as a “big erotic artist,” has encountered unexpected obstacles. The hype of the designer economy is only relevant “if you’re a certain type of designer with a certain type of product,” they said.

Even Yam, from Patreon, recognizes the limits of the burgeoning estate. He anticipates a future in which social media giants and designer economy brands are completely avoidable. Each creator will instead have their own bespoke platform, “their own top-to-bottom world”, from the underlying technology to the published content – a “property economy”. For now, however, the bulk of users will continue to rely on the pre-established attention economy for the bulk of their digital consumption. “Facebook, Instagram, YouTube, these are still so dominant,” Jin said. “Today, no one can find anyone on Patreon; you go there after finding them. In other words, to be a creator you still have to be an influencer after all.


Favorites of New Yorkers


Source link

]]>
Notice concerning the terms and conditions relating to the issuance of share purchase options of the share-based compensation type (share acquisition rights) https://www.ipass.net/notice-concerning-the-terms-and-conditions-relating-to-the-issuance-of-share-purchase-options-of-the-share-based-compensation-type-share-acquisition-rights/ Thu, 15 Jul 2021 09:01:00 +0000 https://www.ipass.net/notice-concerning-the-terms-and-conditions-relating-to-the-issuance-of-share-purchase-options-of-the-share-based-compensation-type-share-acquisition-rights/

Company name: Internet Initiative Japan Inc.
Company representative: Eijiro Katsu, President and Deputy Director
(Stock code number: 3774, the first section of the Tokyo Stock Exchange)
Contact: Akihisa Watai, Senior Managing Director and Chief Financial Officer
PHONE: 81-3-5205-6500

TOKYO, July 15, 2021 (GLOBE NEWSWIRE) – Internet Initiative Japan Inc. (“IIJ”, the “Company”, TSE1: 3774) hereby announces that it has determined the remaining terms and conditions regarding the issuance of actions-compensation- type stock options (“Stock Acquisition Rights”), decided by the Board of Directors of the IIJ on June 29, 2021, to be allocated to directors (excluding part-time and external directors) and leaders of the IIJ, as follows.

1. Total number of Share Purchase Rights
70 rights

2. Class and total number of shares underlying the Share Purchase Rights
28,000 ordinary shares of the Company (the number of shares to be issued or transferred for each right to acquire shares will be 400 shares)

3. Amount to be paid in exchange for the Share Purchase Rights
JPY 1,258,400 per share purchase right (JPY 3,146 per common share)

Acquisition rights are granted to directors (excluding part-time and outside directors) and senior executives of IIJ by offsetting their monetary compensation claims against the company and their obligations to pay for it. allocation of rights to acquire shares.

4. Persons to be allocated the rights to acquire shares, number of persons and number of rights to acquire shares to be allocated:

Directors (excluding part-time and external directors) of the IIJ

8 administrators

41 rights

Leaders of the IIJ

15 senior management

29 rights

About Internet Initiative Japan Inc.
Founded in 1992, IIJ is one of the leading providers of complete network and Internet access solutions in Japan. IIJ and the companies in its group provide complete network solutions that are primarily aimed at high-end businesses. The services of the IIJ include high quality Internet connectivity services, mobile services, security services, cloud services and systems integration. Additionally, IIJ operates one of the largest Internet backbone networks in Japan, which is connected to the US, UK and Asia. IIJ listed on the First Section of the Tokyo Stock Exchange in 2006.

For any request, contact:
IIJ Investor Relations
E-mail: ir@iij.ad.jp Url: https://www.iij.ad.jp/en/ir


Source link

]]>
Five Little-Known Facts About Stock Options https://www.ipass.net/five-little-known-facts-about-stock-options/ Tue, 13 Jul 2021 22:10:48 +0000 https://www.ipass.net/five-little-known-facts-about-stock-options/

Option symbols

The OCC option symbol can consist of up to 4 parts:

  • Root symbol of the underlying stock or ETF, filled with spaces of up to 6 characters
  • Strike price, like price x 1000, front padded 0 to 8 digits
  • Expiration date, 6 digits in YY / MM / DD format
  • Option type, either P or C, for sale or call

Examples:

  • AAPL: AAPL210723C145 – This symbol represents a call to Apple, expiring July 23, 2021, with an exercise price of $ 145.
  • AMZN: AMZN210917P3700 – This symbol represents a put on Amazon, expiring September 17, 2021, with a strike price of $ 3,700.

Buy an option

If you have an option, you do not have to buy the underlying instrument; when you buy a call option, you have the right to BUY shares at the strike price of your option. You can also sell the option itself before expiration.

Likewise, when you buy a put option, you have the right to SELL stocks at the strike price of your option by exercising it, but like call options, you can also sell the sales contract before the exercise. ‘expiry.

Sell ​​an option

First, you can sell an option in which you don’t own any shares! However, if you sell a call option, you are obligated to deliver the underlying asset at the strike price at which the call option was sold if the buyer exercises their right to take delivery. If they don’t exercise, you keep the premium for which you sold the option. Put options are the other way around, if you sell a put option you are obligated to buy the underlying asset if you exercise it.

To sell means to credit and to buy means to debit

Options on PURCHASE are purchased at a DEBIT to the buyer and should be treated as assets. So when you buy an option, the money is debited from your brokerage account. It’s just like buying a stock.

As mentioned above, you can also sell an option, without owning the shares. Options once SOLD are sold on CREDIT to the seller. When you sell an option, it should be considered a liability and money is added to the brokerage account at the time of the sale. Not much is guaranteed in the market, but it is. However, you cannot withdraw this money until the transaction has been closed. This money is generally used to make up the margin required for writing options.

Every day on Options trading signals our resident specialist, Neil Szczepanski, performs defined risk operations that protect us from black swan events 24/7. Many may think that this is what stop losses are for. Well, remember the markets are only open about 1/3 of the hours a day. Therefore, a stop loss only protects you for 1/3 of each day. Actions can go up or down. With options, you are always protected because we define the risk in a spread. We cover with multiple tabs which are still in place once you own it.

My team and I have been building and developing fully systematic algorithmic trading strategies for many years and can tell you unless you have a solid foundation for when and where there are opportunities in market trends. , you are probably going to spend your money. failed exchanges. Although I have already completed the first live presentation, I will be hosting another one at July Wealth365 Summit July 16 at 12 p.m. The Summit is free and offers unprecedented learning opportunities… plus a potential prize or two!

Have a nice day!

For an overview of all of today’s economic events, check out our economic calendar.

Chris Vermeulen
Founder and Chief Market Strategist
www.TheTechnicalTraders.com


Source link

]]>
Cardiff Oncology (CRDF) Announces Appointments of Katherine L. Ruffner, MD, as Chief Medical Officer and James E. Levine as Chief Financial Officer https://www.ipass.net/cardiff-oncology-crdf-announces-appointments-of-katherine-l-ruffner-md-as-chief-medical-officer-and-james-e-levine-as-chief-financial-officer/ Mon, 12 Jul 2021 12:11:09 +0000 https://www.ipass.net/cardiff-oncology-crdf-announces-appointments-of-katherine-l-ruffner-md-as-chief-medical-officer-and-james-e-levine-as-chief-financial-officer/


News and research before you hear about it on CNBC and others. Claim your 1-week free trial for StreetInsider Premium here.


Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including KRAS-mutated colorectal cancer, the cancer pancreatic and castration-resistant prostate cancer, today announced the appointments of Katherine L. Ruffner, MD, as Chief Medical Officer (CMO) and James E. Levine as Chief Financial Officer (CFO ).

Dr. Ruffner has over 25 years of experience in clinical care, oncology biotechnology, and pharmaceutical drug development. Mr. Levine has extensive investment and investment banking experience in the biotechnology industry, including corporate finance, capital markets and business development. In their newly created roles at Cardiff Oncology, Dr Ruffner will be responsible for overseeing the strategy and execution of clinical programs, as well as identifying and evaluating opportunities for pipeline expansion. In his role as Chief Financial Officer, Mr. Levine will guide Cardiff Oncology’s financial strategy and lead its business development efforts, which will focus on maintaining an optimal financial balance between benefits and risks in each of the company’s programs. . Mr. Levine will also be the principal financial and accounting officer of the Company.

“With these appointments, we have continued to achieve our goal of strengthening our leadership team through the addition of highly talented individuals with complementary skills,” said Mark Erlander, Ph.D., Managing Director of Cardiff Oncology. “They come at a time of significant opportunity and growth for the company, as our core program in KRAS-mutated metastatic colorectal cancer is close to reaching significant clinical milestones and we have a meaningful and exciting platform. new clinical indications on the horizon. Katherine’s extensive experience in clinical oncology care and drug development, including advancing new cancer treatments towards regulatory approval, makes her the perfect fit to lead the development of onvansertib as we work to advance our clinical programs His talents, along with Jamie’s track record in funding clinical-stage biotechnology companies, Leading preclinical and clinical collaborations in business development and business partnerships will be essential to our continued evolution as an e company and our commitment to increasing shareholder value. We are delighted to welcome Katherine and Jamie to our team. “

“Onvansertib, in combination with other cancer treatments, has the potential to address unmet patient needs for a number of critically important cancer indications that are currently underserved by available standard treatments,” said the Dr Ruffner. “I am delighted to join the Cardiff oncology team to advance these important potential new treatment options in an environment that combines a rare blend of the agility of a clinical stage biotech company with the resources, l expertise and thoroughness of a much more mature company. . “

Mr. Levine added: “This is a pivotal time to join Cardiff Oncology. With a strong financial base, a base of healthcare-focused institutional investors, and promising clinical data, the company is well positioned for upcoming clinical and preclinical catalysts. I look forward to working with my new colleagues as we strive to generate shareholder value and, more importantly, meet the medical needs of cancer patients through the continued clinical development of onvansertib. “

Bios of appointees

Dr Ruffner is a United States-trained hematologist / oncologist and brings extensive experience in clinical development and clinical care in oncology, from early clinical phase to post-marketing, both within large companies. pharmaceuticals and specialized biotechnology companies. Most recently, Dr. Ruffner served as Vice President of Clinical Development for ALX Oncology, where she led the strategy and execution of their initial clinical asset on a number of different malignant tumors, both tumors solid and hematologic, and has achieved rapid clinical growth from a single open-label trial in two countries to a program with six global trials in five different cancer indications. Prior to joining ALX, she was Global Clinical Chief Consultant for Lumoxiti at Acerta / Astra Zeneca, and from April 2008 to February 2019, she held several clinical development positions in the field of oncology, most recently as Vice President, Clinical Development for CTI Biopharma, where she oversaw the design of the phase 3 confirmation protocol for pacritinib in myelofibrosis. Previously, Dr. Ruffner was Senior Director, Clinical Development / Medical Affairs for Seattle Genetics, and prior to that, Clinical Head of Immuno-Oncology Agent pidilizumab in Hematologic Malignancies at Medivation. Earlier in his career, Dr. Ruffner worked in clinical development in oncology at Pfizer, Biogen and Amgen in addition to providing clinical care to patients undergoing treatment for hematologic malignancies.

Dr. Ruffner received a BS in Biology from Duke University and an MD from the University of Tennessee. She then completed her residency in internal medicine at the University of Michigan and her oncology fellowship at the University of Washington / Fred Hutchinson Cancer Research Center. Prior to joining the industry, she was an Assistant Professor at Vanderbilt University from 2002-2007 in the Faculty of Hematopoietic Stem Cells.

Mr. Levine joins Cardiff Oncology with extensive experience in merchant and investment banking with private and public biotech and pharmaceutical companies. Prior to joining Cardiff Oncology, Mr. Levine served as CFO of Cidara Therapeutics, where he led the financial aspects of major preclinical and clinical collaborations with Janssen Pharmaceuticals (part of Johnson & Johnson) and Mundipharma with a combined value of over $ 1.3 billion. . Previously, Mr. Levine was President and CEO of Sapphire Energy Inc., a privately held industrial biotechnology company that was sold to two groups of private investors. He also held the same roles at Verenium Corp., where he negotiated six product marketing and asset sales partnerships, before selling the company to BASF. Previously, he was also managing director of the investment banking division of Goldman Sachs & Co., within its healthcare and energy groups.

Mr. Levine holds an MBA in Finance from the Wharton School at the University of Pennsylvania and a BA in Economics from Brandeis University.

Nasdaq Listing Rule 5635 (c) (4) Incentive Grants

In connection with the arrival of Dr Ruffner and Mr Levine at Cardiff Oncology, the board of directors of the company has approved the grant of non-qualifying stock options for the purchase of 200,000 and 390,000 common shares of Cardiff Oncology, respectively, outside of Cardiff Oncology 2021. Stock Omnibus Incentive Plan. The stock options were granted as significant incentives for Dr Ruffner and Mr Levine to become employees of Cardiff Oncology in accordance with Nasdaq listing rule 5635 (c) (4). The options were granted to Dr. Ruffner and Mr. Levine on July 12, 2021 and have an exercise price of $ 6.55 per share, which is the closing price of Cardiff Oncology common stock on the day immediately preceding the Date of grant. Options vest over four years with 25% vesting after 12 months and the remaining shares vesting monthly over the next 36 months, subject to the continued employment of Dr. Ruffner and Mr. Levine at Cardiff Oncology on those dates. acquisition.


Source link

]]>
Jaguar Announces Filing of Circular for Its Annual General and Special Meeting of Shareholders https://www.ipass.net/jaguar-announces-filing-of-circular-for-its-annual-general-and-special-meeting-of-shareholders/ Thu, 08 Jul 2021 20:31:00 +0000 https://www.ipass.net/jaguar-announces-filing-of-circular-for-its-annual-general-and-special-meeting-of-shareholders/

Toronto, Ontario – (Newsfile Corp. – July 8, 2021) – Jaguar Financial Corporation (TSXV: JFC.H) (the “Company” or “Jaguar“) is pleased to announce the filing of its Management Information Circular dated June 28, 2021 (the”Circular“) and related meeting documents in connection with the annual general and special meeting of shareholders of the Company (the”Shareholders“) to be held at the Company’s offices at 1 Adelaide Street East, Suite 801, Toronto, Ontario M5C 2V9 at 10:00 a.m. (Toronto time) on Monday August 9, 2021 (the”Meeting“). The Board of Directors of the Company (the”advice“) set June 28, 2021 as the registration date to determine the shareholders entitled to receive the notice and vote at the meeting.

In addition to the annual approvals required under the Business Corporations Act (Ontario) and the TSX Venture Exchange (the “TSXV“), including (i) the election of the Board; (ii) the appointment of the auditor of the Company for the ensuing year; and (iii) the re-approval of the stock option plan of the Company (the “Option plan“) for the following year, the Company will seek Shareholder approval for the following (collectively, the”Meeting resolutions“):

  1. setting the number of directors on the Board at three (3);

  2. fix the number of directors on the board from time to time within the limits of the minimum and maximum number of directors indicated in the articles of association of the Company, in accordance with article 125 (3) of the Business Corporations Act (Ontario) provided that the total number of directors so established may not exceed one-third of the number of directors elected at the previous annual general meeting of shareholders;

  3. delisting of the ordinary shares of the Company (the “Ordinary actions“) TSXV, as more particularly described in the Circular;

  4. amend the articles of incorporation of the Company to change the name of the Company to a name determined by the Board in its sole discretion, as more particularly described in the Circular;

  5. approving the continuation of the Company from Business Corporations Act (Ontario) to Business Corporations Act (British Columbia) including the adoption of new articles and notices of articles, as more particularly described in the Circular;

  6. approving the revision of the price of 1,010,039 previously granted stock options (each a “Option“) issued to insiders of the Company (the”Retarification“) under the Option Plan at a new exercise price of $ 0.125 or at a higher price that may be demanded by the TSX Venture Exchange. The price revision is intended to bring the exercise price of the options into line with the current market price of the common shares Price revision is subject to approval by the TSX Venture Exchange and the approval of disinterested shareholders of the Company in accordance with TSX Venture Exchange Policy 4.4 – Stock options. Further details on re-pricing are included in the circular; and

  7. to deal with any other matter which may be duly submitted to the meeting.

The Company has chosen to use notification and access (“Notice and access“) the provisions of Regulation 54-101 – Communications with Beneficial Owners of Securities of a Reporting Issuer and Regulation 51-102 – Continuous information obligations distribute the documents of the Meeting to the Shareholders. Notice and Access is a set of rules that allows issuers to post electronic versions of proxy documents on SEDAR and on an additional website, rather than sending hard copies to shareholders. Shareholders have the right to request hard copies of any proxy documents posted online by the Company under Notice and Access.

Meeting documents, including the circular, will be available under the company profile at www.sedar.com and https://docs.tsxtrust.com/2037 no later than July 8, 2021. The Company will provide any shareholder, upon request to the TSX Trust Company (“TSX Trust“), the transfer agent of the Company, a hard copy of the Circular and the audited financial statements of the Company for the years ended December 31, 2020 and 2019 or the management report of the Company filed with the securities authorities relevant securities during the In order to allow a reasonable period of time to request shareholders to receive and examine a hard copy of the circular or other document before the proxy deadline (as set out below), any shareholder who wishes to receive paper copies of any meeting material must submit their written request to TSX Trust by July 19, 2021.

The deadline for the return of proxies for the meeting is Thursday, August 5, 2021 at 10:00 a.m. (Toronto time). Voting results for items to be considered by Jaguar shareholders at the Meeting will be announced after the Meeting and posted on SEDAR.

This announcement is for informational purposes only and does not constitute a solicitation or a proxy.

About Jaguar Financial Corporation

Jaguar is a Canadian merchant bank that typically invests in companies that Jaguar deems to be undervalued, neglected and undervalued. Investments made are usually motivated by events, for example when an investment is made in a company that is the subject of a takeover bid or when another change is initiated by a third party or a shareholder of the company. concerned. Jaguar’s goal is to help the management of the undervalued company create value that the market lacks.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of TSXV) accepts responsibility for the adequacy or accuracy of this press release.

For more information :

Michael lerner
Chief Executive Officer, Chief Financial Officer and Director
T: 416-710-4906
E: mlerner10@gmail.com

Forward-looking statements and other caveats

This press release contains “forward-looking information” which may include, but is not limited to, information regarding activities, events or developments that the Company expects or anticipates will occur or may occur in the future. to come up. This forward-looking information is often, but not always, identified by the use of words and phrases such as “plans”, “expects”, “is planned”, “budget”, “planned”, “estimates”, “forecasts”. “,” Intends “,” anticipates “or” believes “or variations (including negative variations) of these words and expressions, or state that certain actions, events or results” could “,” could “, “Could”,, or “will” be taken, occur or be reached. This forward-looking information includes, among other things, information concerning: expectations regarding the approval of all or part of the resolutions of the meeting and the effect they will have on the business and operations of the Company; the Company’s ability to successfully achieve its business objectives; and expectations regarding other economic, business and / or competitive factors.

Investors are cautioned that forward-looking information is not based on historical facts but rather reflects management’s expectations, estimates or projections regarding future results or events based on management’s opinions, assumptions and estimates believed to be reasonable at the time. date the declarations are made. Although the Company believes that the expectations reflected in this forward-looking information are reasonable, such information involves risks and uncertainties, and such information should not be relied upon because unknown or unforeseeable factors could have material adverse effects on the Company. the future results, performance or achievements of the Company. Some of the key factors that could cause actual results to differ materially from those projected in the forward-looking information include the following: shareholders, the TSX Venture Exchange and / or government authorities may not approve all of some of the applicable resolutions. of the assembly; the potential impact of announcing or consuming assembly resolutions on relations with regulators and investors; and changes in economic, trade and general political conditions, including changes in financial markets caused by the COVID-19 pandemic. This forward-looking information may be affected by risks and uncertainties relating to the activities of the Company and to market conditions.

This information is subject in its entirety to the caveats and information on risk factors contained in the documents filed by the Company with the Canadian securities regulators, including, but not limited to the financial statements. Audits of the Company and the related MD&A for the year ended December. December 31, 2020 and 2019 filed with securities regulators in certain provinces of Canada and available under the Company’s profile on SEDAR at www.sedar.com.

If one or more of these risks or uncertainties materialize, or if the assumptions underlying the forward-looking information prove to be incorrect, the actual results could differ materially from those described in this document as being intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify risks, uncertainties and important factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or planned. The Company does not intend and assumes no obligation to update this forward-looking information, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/89808


Source link

]]>
DiDi’s $ 3 billion options salary: who could have won? https://www.ipass.net/didis-3-billion-options-salary-who-could-have-won/ Wed, 07 Jul 2021 12:15:21 +0000 https://www.ipass.net/didis-3-billion-options-salary-who-could-have-won/

The deletion of more than 20% of DiDi Global shares from the New York Stock Exchange on Tuesday following a cybersecurity investigation in China just two days after its trading debut in the United States drew sharp criticism and appeals collectives. Controversy also erupted following more detailed coverage of a June 28 announcement by the ridesharing service that “certain directors and officers” were granted options at a “nominal strike price per share” which will result in stock compensation expenses of $ 3 billion in the loss-making company. The US SEC’s file did not indicate which directors or officers were addressed.

Below is a list of DiDi’s board members and executive directors, based on the company’s prospectus and biographies filed with the SEC. The ties to Goldman and Alibaba stand out, as well as the billionaire status of at least three board members.

Will Cheng: Cheng has been the founder and chairman of DiDi since January 2013, as well as CEO since February 2015. Cheng worked at Alibaba from 2005 to 2011, most recently as vice chairman of Alipay, and before that, in a number of sales. related posts, including that of Regional Director. Forbes estimates that Cheng held more than $ 3 billion in DiDi shares yesterday.

Jean Liu: Co-founder and chairman of DiDi since December 2014, Liu is the daughter of Chinese technology pioneer Liu Chuanzhi. “It advocates a more collaborative approach for the new technologies sector in order to work with policy makers, public transport organizations and the automotive industry to address global challenges in terms of mobility, environment and employment”, indicates the company’s prospectus. Previously, Liu was managing director of Goldman Sachs’ Principal Investment Area in Beijing, primarily responsible for private equity investments, portfolio management and investor relations in China, the prospectus said. Liu is also a board member of fashion heavyweight Kering.

Stephen Zhu: Zhu has been a director since June 2016 and senior vice president since January 2019, responsible for strategy, capital markets and international affairs. Prior to joining DiDi in 2014, Zhu was executive director of Goldman Sachs’ “Principal Investment Area” in Hong Kong, the prospectus says. He has also worked at Bain Capital, Morgan Stanley and the Boston Consulting Group.

Martin Lau: A director since 2015, Lau is chairman of Chinese internet heavyweight Tencent Holdings and today holds a fortune of $ 3.4 billion on the Forbes list of real-time billionaires. Prior to joining Tencent, Mr. Lau was executive director of the investment banking division of Goldman Sachs (Asia) LLC and chief operating officer of its telecommunications, media and technology group. Lau is also a director at China tech

leaders such as Kingsoft, Meituan, Vipshop, Tencent Music Entertainment Group and JD.com.

Adrian Perica: Director since June 2016 and independent director since June 29, 2021, Perica is Apple’s vice president of corporate development, reporting to CEO Tim Cook. Previously, Perica also worked at Goldman Sachs and Deloitte Consulting.

Daniel Zhang: Director of DiDi since April 2018, Zhang has been Chairman of the Alibaba Group since September 2019 and its CEO since May 2015.

Wang Gaofei: Wang has been an independent director since June 29, the day before DiDi’s US listing. He was CEO of Weibo and previously worked at Sina, two influential media companies in China.

Wang Yusuo: Wang chairs ENN, a Chinese energy conglomerate, and today has a fortune of $ 8.6 billion on the Forbes list of real-time billionaires that he shares with his family. Wang joined as an independent director since June 29, a day before DiDi’s listing.

Bob Zhang: Zhang is co-founder and CTO. Prior to joining DiDi, Zhang was a senior technology manager at Baidu.

Alan Zhuo: Zhuo has been CFO since April 2021 and has held other positions at DiDi previously. Prior to joining DiDi, Zhuo worked at Sculptor Capital Management, Goldman Sachs and Morgan Stanley.

Rui Wu: Wu has been co-founder and vice president since September 2015 with responsibility for our risk control and compliance functions. Prior to 2012, Wu worked at Alibaba in sales management.

Jinglei Hou: Hou has been responsible for mobility security since April 2019.

Min Li: Li is vice president of public communications.

Shu Sun: Sun has been CEO of DiDi’s carpool business in China since December 2020. Prior to joining DiDi, Sun was a partner at Tsing Capital from 2014 to 2015 and a senior partner at Bloomberg New Energy Finance from 2009 to 2014.

David Xu: Xu has been Vice President and Head of Capital Markets since March 2018. Previously, he worked for Apax Partners, UBS Investment Bank and Goldman Sachs Asia.

@rflannerychina


Source link

]]>